Health Care & Life Sciences » Pharmaceuticals | Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
13,678.90
22,400.00
66,227.00
189,482.00
236,707.00
213,312
Cost of Goods Sold (COGS) incl. D&A
7,515.80
52.00
15,647.00
55,306.00
57,186.00
61,916
Gross Income
6,163.10
22,348.00
50,580.00
134,176.00
179,521.00
151,396
SG&A Expense
14,618.20
-
48,020.00
81,719.00
103,723.00
104,928
EBIT
8,455.10
26,260.00
2,560.00
52,457.00
75,798.00
46,468
Unusual Expense
2,998.00
-
-
856.00
1,808.00
9,852
Non Operating Income/Expense
3.20
4.00
-
1,742.00
-
-
Interest Expense
1,496.40
-
11.00
-
1,136.00
2,736
Pretax Income
6,947.20
26,260.00
2,574.00
53,427.00
72,945.00
34,038
Income Tax
898.70
4,236.00
3.00
28,026.00
21,002.00
2,135
Consolidated Net Income
6,048.50
22,024.00
2,571.00
81,453.00
51,943.00
31,903
Net Income
6,048.50
22,024.00
2,571.00
81,453.00
51,943.00
31,903
Net Income After Extraordinaries
6,048.50
22,024.00
2,571.00
81,453.00
51,943.00
31,903
Net Income Available to Common
9,885.30
22,024.00
2,571.00
81,453.00
51,943.00
31,903
EPS (Basic)
0.71
1.56
0.16
4.96
3.27
2.09
Basic Shares Outstanding
14,020.10
14,032.80
15,250.20
15,533.70
15,102.90
14,768.60
EPS (Diluted)
0.71
1.57
0.16
4.96
3.27
2.09
Diluted Shares Outstanding
14,020.10
14,032.80
16,253.80
16,434.10
15,908.20
15,278.70
EBITDA
8,320.10
26,208.00
2,672.00
54,046.00
79,545.00
50,138
Other Operating Expense
-
48,608.00
-
-
-
-
Non-Operating Interest Income
3.20
4.00
25.00
84.00
91.00
158
Preferred Dividends
3,836.80
-
-
-
-
-

About Eagle Pharmaceuticals

View Profile
Address
50 Tice Boulevard
Woodcliff Lake New Jersey 07677
United States
Employees -
Website http://www.eagleus.com
Updated 07/08/2019
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban; ryanodex; docetaxel injection, non-alcohol formulation; and bendeka. The company was founded by Scott L.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.